US Biomax, Inc.

PR953

Prostate cancer tissue array with matched normal adjacent tissue and metastatic bones, with TNM, Gleason scores, PSA level and survival data, 40 cases/95 cores, replaced by PR954

Microarray Panel:Prostate adenocarcinoma tissue microarray, duplicated cores, 36 cancer and 8 of which has matched normal adjacent tissue and 3 cases of metastasis in bones and 1 in abdominal wall,with follow-up data
Cores:95
Cases:40
Layout:12 cols × 8 rows
Core Diameter:1.5 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:

Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.

Notes:1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning.
2. Most of the TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). We still recommend 30 minutes of baking at 60°C before putting into xylene for de-paraffinization procedure.


Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
123456789101112
A Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro
B Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro
C Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro
D Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro
E Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro
F Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro
G Abd Abd Bon Bon Bon Bon Bon Bon Pro Pro Pro Pro
H Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Pro Car
Legend: Abd - Abdominal wall, Bon - Bone, Car - Carbon, Pro - Prostate

- Carbon, - Malignant tumor (stage II), - Malignant tumor (stage III), - Malignant tumor (stage IV), - NAT

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Stage Gleason Score TNM Months Type †
A1, A2 1 M 68 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
A3, A4 2 M 64 Prostate Adenocarcinoma II 7 T2cN0M0 . Malignant
A5, A6 3 M 71 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
A7, A8 4 M 64 Prostate Adenocarcinoma III 10 T3aN0M0 . Malignant
A9, A10 5 M 59 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
A11, A12 6 M 65 Prostate Adenocarcinoma IV 8 T4N0M0 . Malignant
B1, B2 7 M 73 Prostate Adenocarcinoma II 7 T2cN0M0 . Malignant
B3, B4 8 M 69 Prostate Adenocarcinoma II 7 T2cN0M1 . Malignant
B5, B6 9 M 62 Prostate Adenocarcinoma II 7 T2cN0M1 . Malignant
B7, B8 10 M 66 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
B9, B10 11 M 60 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
B11, B12 12 M 70 Prostate Adenocarcinoma IV 7 T4N0M0 . Malignant
C1, C2 13 M 65 Prostate Adenocarcinoma III 9 T3bN0M1 . Malignant
C3, C4 14 M 67 Prostate Adenocarcinoma IV 9 T3bN1M0 . Malignant
C5, C6 15 M 69 Prostate Adenocarcinoma III 7 T3bN0M0 . Malignant
C7, C8 16 M 69 Prostate Adenocarcinoma III 7 T3aN0M1 . Malignant
C9, C10 17 M 70 Prostate Adenocarcinoma III 7 T3aN0M1 . Malignant
C11, C12 18 M 58 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
D1, D2 19 M 71 Prostate Adenocarcinoma II 7 T2cN0M0 . Malignant
D3, D4 20 M 70 Prostate Adenocarcinoma III 7 T3bN0M0 . Malignant
D5, D6 21 M 59 Prostate Adenocarcinoma II 6 T2bN0M0 . Malignant
D7, D8 22 M 63 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
D9, D10 23 M 72 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
D11, D12 24 M 66 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant
E1, E2 25 M 70 Prostate Adenocarcinoma II 7 T2cN0M1 . Malignant
E3, E4 26 M 68 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant
E5, E6 27 M 63 Prostate Adenocarcinoma III 10 T3bN0M1 . Malignant
E7, E8 28 M 57 Prostate Adenocarcinoma III 7 T3bN0M0 . Malignant
E9, E10 29 M 72 Prostate Adenocarcinoma III 8 T2cN0M0 . Malignant
E11, E12 30 M 70 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant
F1, F2 31 M 75 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
F3, F4 32 M 62 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
F5, F6 33 M 63 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
F7, F8 34 M 53 Prostate Adenocarcinoma III 9 T3bN0M0 . Malignant
F9, F10 35 M 63 Prostate Adenocarcinoma III 8 T3bN0M0 . Malignant
F11, F12 36 M 44 Prostate Adenocarcinoma III 7 T3bN0M1 . Malignant
G1, G2 37 M 65 Abdominal wall Metastatic adenocarcinoma from prostate IV . M1 36 Malignant
G3, G4 38 M 61 Bone Metastatic adenocarcinoma from prostate IV . M1 32 Malignant
G5, G6 39 M 69 Bone Metastatic adenocarcinoma from prostate IV . M1 34 Malignant
G7, G8 40 M 59 Bone Metastatic adenocarcinoma from prostate IV . M1 0 Malignant
G9, G10 41 M 69 Prostate Normal (match of #8) . . . . NAT
G11, G12 42 M 62 Prostate Normal (match of #9) . . . . NAT
H1, H2 43 M 65 Prostate Normal (match of #13) . . . . NAT
H3, H4 44 M 69 Prostate Normal (match of #16) . . . . NAT
H5, H6 45 M 70 Prostate Normal (match of #17) . . . . NAT
H7, H8 46 M 70 Prostate Normal (match of #25) . . . . NAT
H9, H10 47 M 63 Prostate Normal (match of #27) . . . . NAT
H11 48 M 44 Prostate Normal (match of #36) . . . . NAT

* Month, interval between primary and metastatic cancer
** TNM and stage, AJCC Cancer Staging Manual (6th Edition), pTNM, pathological TNM


† For precise diagnosis, refer to pathology description.

Supplementary Data

Pos No. PSA (ng/ml) Residual tumor Follow-up months Follow-up result Cause of death Remark
A1, A2 1 . . . . . .
A3, A4 2 30 R0 60 alive . .
A5, A6 3 60.4 R1 55 alive . .
A7, A8 4 7.4 R1 47 alive . .
A9, A10 5 9.8 R1 44 alive . .
A11, A12 6 34.9 R1 43 alive . .
B1, B2 7 48.1 R1 42 alive . .
B3, B4 8 10.6 R0 42 alive . .
B5, B6 9 37.3 R1 39 alive . .
B7, B8 10 1.2 R1 39 alive . .
B9, B10 11 40 R1 39 alive . .
B11, B12 12 7 R1 37 alive . .
C1, C2 13 17.5 R1 23 dead cancer .
C3, C4 14 13.1 R1 34 alive . .
C5, C6 15 1.1 R1 33 alive . .
C7, C8 16 17.6 R1 27 alive . .
C9, C10 17 9 R1 26 alive . .
C11, C12 18 5.8 R0 26 alive . .
D1, D2 19 31.4 R1 24 alive . .
D3, D4 20 14.4 R1 19 alive . .
D5, D6 21 18.3 R0 18 alive . .
D7, D8 22 16.6 R1 17 alive . .
D9, D10 23 . R1 16 alive . .
D11, D12 24 10.8 R1 17 dead cancer .
E1, E2 25 . R0 15 alive . .
E3, E4 26 26.9 R1 15 alive . .
E5, E6 27 . R1 15 alive . .
E7, E8 28 25 R1 15 alive . .
E9, E10 29 16.8 R1 15 alive . .
E11, E12 30 0.5 R1 15 alive . .
F1, F2 31 98 R1 15 alive . .
F3, F4 32 . R1 15 alive . .
F5, F6 33 91 R1 14 alive . .
F7, F8 34 161 R1 17 dead cancer .
F9, F10 35 13 R1 13 alive . .
F11, F12 36 . R1 11 alive . .
G1, G2 37 . . . . . .
G3, G4 38 . . . . . .
G5, G6 39 . . . . . .
G7, G8 40 . . . . . .
G9, G10 41 . . . . . .
G11, G12 42 . . . . . .
H1, H2 43 . . . . . .
H3, H4 44 . . . . . .
H5, H6 45 . . . . . .
H7, H8 46 . . . . . .
H9, H10 47 . . . . . .
H11 48 . . . . . .

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis


Find overlapping cases with this tissue array: